Search

Your search keyword '"THIERY, GUILLAUME"' showing total 296 results

Search Constraints

Start Over You searched for: Author "THIERY, GUILLAUME" Remove constraint Author: "THIERY, GUILLAUME"
296 results on '"THIERY, GUILLAUME"'

Search Results

3. Renal replacement therapy initiation strategies in comatose patients with severe acute kidney injury: a secondary analysis of a multicenter randomized controlled trial

5. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

8. Long-term outcomes after severe acute kidney injury in critically ill patients: the SALTO study

9. Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial

10. Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)

11. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial

13. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

14. Factors Associated with Fatigue in COVID-19 ICU Survivors.

15. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

16. Cardiorespiratory Fitness and Neuromuscular Function of Mechanically Ventilated ICU COVID-19 Patients

17. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

19. Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic Modelling.

20. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

22. Vascular access for renal replacement therapy among 459 critically ill patients: a pragmatic analysis of the randomized AKIKI trial

23. Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial

24. Dosing Regimen for Cefotaxime Should Be Adapted to the Stage of Renal Dysfunction in Critically Ill Adult Patients—A Retrospective Study.

26. Epidemiology and outcome predictors in 450 patients with hanging-induced cardiac arrest: a retrospective study

27. Cefoxitin versus carbapenems as definitive treatment for Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis

28. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)

29. Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial

30. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

31. Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)

32. Epidemiology and outcome predictors in 450 patients with hanging-induced cardiac arrest: a retrospective study

33. Long-term outcome in neuroZika: When biological diagnosis matters

35. Additional file 1 of ICU health care workers opinion on physician-assisted-suicide and euthanasia: a French survey

37. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

38. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

39. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

41. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2

43. Severe sepsis and septic shock associated with chikungunya virus infection, Guadeloupe, 2014

44. L’après-réanimation, une étape, des enjeux

45. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

47. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

48. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

49. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

50. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Catalog

Books, media, physical & digital resources